TITLE:
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

CONDITION:
Myelodysplastic Syndromes

INTERVENTION:
Darbepoetin Alfa

SUMMARY:

      The purpose of this study is to assess the effect of 13 weeks of darbepoetin alfa treatment
      on erythroid response in anemic subjects with low risk Myelodysplastic Syndrome (MDS).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Eligibility Criteria: General: - Low risk MDS (low or intermediate-1 risk as defined by
        IPSS) and FAB classification of RA, RARS, or RAEB with blasts less than or equal to 10%
        determined via a bone marrow biopsy and CBC - Adequate iron stores determined by bone
        marrow film or section staining for iron via a bone marrow biopsy - ECOG Performance
        status score of 0, 1, or 2 Laboratory: - Local laboratory screening Hgb less than or equal
        to 11.0g/dL - Adequate renal function (serum creatinine concentration less than or equal
        to 2.0 mg/dL) - Adequate liver function (total bilirubin less than or equal to 2 times,
        ALT less than or equal to 3 times, and AST less than or equal to 3 times the upper limit
        of the respective normal range) Ethical: - Must be 18 years of age or older - Provide
        written Institutional Review Board (IRB)-approved informed consent before any screening
        procedures are performed
      
